clinical trial · NCT06179069
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.·phase1·recruiting·n = 339
SCLCZL-1310AtezolizumabCarboplatin
brief summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
started
Jan 23, 2024
primary completion
May 30, 2027
completion
Jul 31, 2027
last updated
Oct 16, 2026
detailed description
This is an open-label, ascending, multiple-dose, phase 1 study evaluating ZL-1310 as a single agent, in combination with Atezolizumab, and in combination with Atezolizumab and Carboplatin in subjects with extensive SCLC.
official title
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol